A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later.
about
Radioiodine Remnant Ablation: A Critical ReviewManagement Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerQuantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometryLong-term efficacy of lymph node reoperation for persistent papillary thyroid cancerCurrent concepts and future directions in differentiated thyroid cancer.The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study.Significance of size of lymph node metastasis on postsurgical stimulated thyroglobulin levels after prophylactic unilateral central neck dissection in papillary thyroid carcinomaAbility of the rhTSH stimulation test to predict relapse in patients with differentiated thyroid carcinoma, after long-term follow-up.Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma.Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection.Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatmentIs there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation?Antithyroglobulin Antibody as a Marker of Successful Ablation Therapy in Differentiated Thyroid Cancer.Use of recombinant human thyroid-stimulating hormone in the management of well-differentiated thyroid cancer.Postablation stimulated thyroglobulin level is an important predictor of biochemical complete remission after reoperative cervical neck dissection in persistent/recurrent papillary thyroid carcinoma.Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid AssociatDetecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin.Clinicopathologic and molecular disease prognostication for papillary thyroid cancer.Preablation Stimulated Thyroglobulin/TSH Ratio as a Predictor of Successful I(131)Remnant Ablation in Patients with Differentiated Thyroid Cancer following Total Thyroidectomy.Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management.Rare metastases of well-differentiated thyroid cancers: a systematic review.Recurrence of papillary thyroid cancer after optimized surgery.Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic 131I in the differentiated thyroid cancers.Trick and treat: Ambushing recurrent tumors before they get out of the door.Nomograms predicting disease-specific regional recurrence and distant recurrence of papillary thyroid carcinoma following partial or total thyroidectomy.Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.Disease outcomes and nodal recurrence in patients with papillary thyroid cancer and lateral neck nodal metastases.Management of differentiated thyroid cancer of the follicular epithelium.Unusual Presentation of Differentiated Thyroid Cancer Metastasis.Evaluation of the highly sensitive Roche thyroglobulin II assay and establishment of a reference limit for thyroglobulin-negative patient samples.Biochemical Testing in Thyroid Disorders.Guidelines for the management of thyroid cancer
P2860
Q26784202-0719F190-A54C-4B36-8DCB-2A25B13D5B11Q26829349-C7BFE548-0B57-42C7-B000-A56F55462729Q30367068-5620380F-6CC3-49C1-9B6B-26FCCEA14D3BQ33370510-36473FBB-5341-463A-BEAC-BEFEF31842EAQ33587809-6321F1E2-8933-413F-BC78-6975DF476998Q33677589-3F2A7E78-2488-4CC9-B5A0-957B75366F26Q34113199-8A65C86B-4B5C-4846-A5E5-0799523365E2Q34260830-F6BD9A1B-BF8B-4997-862C-8BB64720C700Q35042089-E378F9D2-FD4E-4025-8C0C-F4ED12DCE091Q35653514-42D0AAFD-53C4-4574-9CAB-3DAC96492FC1Q35843018-91726428-B18A-40B8-94D6-296505A87243Q35864072-BD1DB9F2-0B6F-4AA1-8F25-686314A2F051Q36124278-27610599-B555-4360-9A00-CB0B6522D528Q36233648-0CE53E51-CBC7-42E6-AFFA-70C11149AA61Q36285155-6AAF955F-0369-4A28-8B30-F0544F9C4C7EQ36377222-3037D70D-BE30-4FFB-B211-B3C332CED2B8Q36578078-EB52D95D-739D-42E0-B846-51DA704DE392Q36837469-CF035672-655C-4B80-A4BD-BA61DBA00A64Q37477557-F5A94618-2B87-47DE-855E-D80BA82A65CFQ37573792-252ED785-0368-4A64-B8D5-37502F584572Q37598938-52C353A7-625E-45BF-9868-CD9553F802F7Q37724978-86ACEB64-92D1-4229-AFE7-4CC6D8BA5989Q37815386-AC36F889-902D-4146-AB89-6A82C98AE743Q38246354-B5B3F163-C9F6-47D0-9BDC-D9EABAAD896EQ38365026-477D2650-31FF-464B-A88C-4CBB06B7853BQ39533339-21F5FF8B-F743-43BC-BBAE-1E5C00E49D07Q42180796-C2EAB3B2-5735-4917-A766-A476B86C49D5Q42280316-7B380DCB-A3FB-45BE-AE6B-7B4F6FBC4A22Q42474502-3024D232-6526-455E-95A2-826099969BBBQ43901807-55EAF089-F4FC-49BB-B0C0-B0624E83617DQ44901402-2B364D26-6125-469B-BFA7-B4FFA032836AQ55033482-279E1F9F-07E3-4A2C-ACED-C7001106DAA3Q55069933-BF914B1F-6D67-4A7F-A1E5-FAD2934B67EBQ55164859-4A27BD14-AC14-4817-9322-EC1D14D14358Q56554243-FC203A12-706F-4E41-9083-15F82B450049
P2860
A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
A single recombinant human thy ...... ses three to five years later.
@en
type
label
A single recombinant human thy ...... ses three to five years later.
@en
prefLabel
A single recombinant human thy ...... ses three to five years later.
@en
P356
P1476
A single recombinant human thy ...... ses three to five years later.
@en
P2093
Ernest L Mazzaferri
Richard T Kloos
P304
P356
10.1210/JC.2005-0492
P407
P577
2005-06-21T00:00:00Z